Glucagon and glucagon-like peptide-1 receptors: promising therapeutic targets for an effective management of diabetes mellitus
While people on GLP-1s for diabetes may need to be on the medicine for life, Jasik says there's a desire from individuals taking the drug for weight loss to stop
We know that it increases the disease risk. Studies have linked weight cycling to cardiovascular disease and diabetes, among other health issues
Many patients report that appetite suppression becomes noticeably stronger by week three, even at these lower doses
Risks and caveats With great promise also comes the risk of side effects, such as gastrointestinal issues, pancreatitis, and other downsides, when taking GLP-1 drugs
Adding dose calculation on top of that amplifies the stress